Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) announced the appointment of Eilon Elmalem as site head of its wholly owned subsidiary Scinai Biopharma Services’ Yavne CDMO facility, effective June 14, 2026. Elmalem, who has supported the company as an external consultant for the past two years, brings more than two decades of biotechnology and pharmaceutical operations experience and will oversee site operations and engineering activities as Scinai continues expanding its contract development and manufacturing platform.
The appointment signals Scinai's strategic focus on strengthening its CDMO capabilities, which are central to the company's business model. By bringing an experienced industry veteran like Elmalem on board, Scinai aims to enhance operational efficiency and scale its manufacturing services to meet growing demand from biotech and pharmaceutical clients. The Yavne facility is a key asset in Scinai's portfolio, offering development and manufacturing services that complement the company's internal pipeline of immunology therapies.
Scinai Immunotherapeutics is a biopharmaceutical company focused on developing innovative immunology therapies. The company is advancing a pipeline of therapeutic candidates licensed from the Max Planck Society and from PinCell S.r.l. In addition to its drug development efforts, Scinai owns Scinai Biopharma Services Ltd., a contract development and manufacturing organization (CDMO) that provides services to other biotechnology and pharmaceutical companies. The CDMO segment is a significant revenue driver and strategic asset, enabling Scinai to leverage its expertise in biologics manufacturing while generating income to support its R&D activities.
The appointment of Elmalem comes as Scinai positions itself for growth in the competitive CDMO market. With his extensive background in biotech operations, Elmalem is expected to drive improvements in site performance, ensure regulatory compliance, and foster innovation in manufacturing processes. This move aligns with the company's broader strategy to capitalize on the increasing outsourcing trend in the biopharmaceutical industry, where companies seek specialized partners for drug development and production.
For more details on the appointment, the full press release is available at https://ibn.fm/VLt3w. The latest news and updates regarding Scinai Immunotherapeutics can be found in the company's newsroom at https://ibn.fm/SCNI.
